scholarly journals Retraction: Efficacy and Safety of Preoperative Intravenous Tranexamic Acid to Reduce Blood Loss During and after Elective Lower‐Segment Cesarean Delivery

2021 ◽  
Vol 11 (4) ◽  
pp. 368-368
Author(s):  
Dalia Nour ◽  
Tarek El Husseiny ◽  
Nada Osman
Keyword(s):  
Blood Loss ◽  
Tranexamic Acid ◽  
Cesarean Delivery ◽  
Efficacy And Safety ◽  
Reduce Blood Loss ◽  
Lower Segment

scholarly journals A comparison of two doses of tranexamic acid to reduce blood loss during cesarean delivery

2015 ◽  
Vol 1 (4) ◽  
Author(s):  
Ben Marzouk Sofiene ◽  
Hannachi Zied ◽  
Ben Nasr Laidi ◽  
Marzougui Yahya ◽  
Maghrebi Hayen
Keyword(s):  
Blood Loss ◽  
Tranexamic Acid ◽  
Cesarean Delivery ◽  
Reduce Blood Loss

The efficacy of Tranexamic Acid Administration in Patients Undergoing Tonsillectomy: An Updated Meta-Analysis

2021 ◽  
pp. 000348942110452
Author(s):  
Cathleen C. Kuo ◽  
Jason C. DeGiovanni ◽  
Michele M. Carr
Keyword(s):  
Blood Loss ◽  
Tranexamic Acid ◽  
Meta Analysis ◽  
Efficacy And Safety ◽  
Intraoperative Blood Loss ◽  
Reduce Blood Loss ◽  
Dichotomous Data ◽  
Significant Difference ◽  
Acid Administration

Objective: There is controversy regarding the efficacy and safety of tranexamic acid (TXA) in reducing tonsillectomy-related hemorrhage. We conducted a systematic review and meta-analysis to evaluate the prophylactic role of TXA in tonsillectomy. Methods: We searched 6 databases to identify studies that directly compare the effect of TXA versus controls in tonsillectomy patients. Standardized mean difference was applied to summate the findings across the studies. Dichotomous data were expressed as relative risk. Results: Ten studies representing a total of 111 898 patients were included. The pooled results showed a significant reduction of intraoperative blood loss by 39.02 ml (SMD = −1.05, 95% CI: −1.91 to −0.20, P = .016) and the rate of post-tonsillectomy hemorrhage (RR = 0.42, 95% CI: 0.28 to 0.65, P < .0001), with no significant difference in reduction of further intervention risk (RR = 0.78, 95% CI: 0.45 to 1.35, P = .373). Conclusions: Overall, this study indicates that TXA may reduce blood loss and frequency of post-operative hemorrhage associated with tonsillectomy. Further large, high-quality clinical trials are still needed to explore TXA’s effect on post-tonsillectomy hemorrhage and the safety of its use.

scholarly journals Intra-Articular Injection of Tranexamic Acid to Reduce Blood Loss after Total Knee Arthroplasty

2014 ◽  
Vol 22 (2) ◽  
pp. 146-149 ◽  
Author(s):  
Bob Jang ◽  
Mark Kao ◽  
Martin T Bohm ◽  
Ian A Harris ◽  
Darren B Chen ◽  
...  
Keyword(s):  
Total Knee Arthroplasty ◽  
Blood Loss ◽  
Tranexamic Acid ◽  
Knee Arthroplasty ◽  
Reduce Blood Loss ◽  
Total Knee

Tranexamic Acid for the Prevention of Blood Loss After Cesarean Delivery

2021 ◽  
Vol 76 (9) ◽  
pp. 524-526
Author(s):  
Loic Sentilhes ◽  
Marie V. Sénat ◽  
Maela Le Lous ◽  
Norbert Winer ◽  
Patrick Rozenberg ◽  
...  
Keyword(s):  
Blood Loss ◽  
Tranexamic Acid ◽  
Cesarean Delivery

scholarly journals The Efficacy and Safety of Fibrin Sealant Versus Tranexamic Acid Administration in Patients Undergoing Hip Arthroplasty: A Meta-analysis

2020 ◽  
Author(s):  
Fan Yong Yong ◽  
deng bo ◽  
Hong Hai Nan ◽  
Zhu Zhong
Keyword(s):  
Blood Loss ◽  
Tranexamic Acid ◽  
Randomized Controlled Trials ◽  
Hip Arthroplasty ◽  
Fibrin Sealant ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Transfusion Rate ◽  
Efficacy And Safety ◽  
Randomized Controlled

Abstract PurposeThe efficacy and safety of topical fibrin sealant (FS) compared with tranexamic acid (TXA) to reduce blood loss after total hip arthroplasty (THA) is not clear. A meta-analysis was conducted to evaluate the efficacy and safety of topical FS versus topical or intravenous TXA for treatment of primary THA.MethodWe searched electronic databases, including PubMed, Embase, and the Cochrane Library to identify studies up to March 2020. The references included in articles were also checked for additional potentially-relevant studies. The language of publication was limited to English. The endpoints included the mean difference (MD) of blood loss, hemoglobin value, and odds ratios (ORs) of transfusion requirements and thrombotic events. Our meta-analysis was performed according to the Guidelines of the Cochrane Reviewer's Handbook and the PRISMA statement. The data of the included studies were analyzed using RevMan 5.3.ResultsA total of four studies (two randomized controlled trials and two non-randomized controlled trials) met the inclusion criteria. Our meta-analysis demonstrated that TXA administration led to significantly different outcomes in terms of transfusion rate (RD = -0.12, 95% CI (-0.23, -0.00), P = 0.05, I2 = 74%) and postoperative hemoglobin levels (WMD = -0.47, 95% CI (-0.74, -021), P = 0.0005, I2 = 3%) compared with topical application of FS in patients undergoing THA. No significant difference was seen in total calculated blood loss (WMD = -86.22, 95% CI (-99.13, -73.31), P < 0.00001, I2 = 96%) or complication rate (RR = 0.98, 95% CI (-99.13, -73.31), P = 0.45, I2 = 0%) between the two groups.ConclusionsTXA administration can effectively decrease the transfusion rate and result in higher postoperative hemoglobin levels without increasing the rate of infection.

Sign in / Sign up

Export Citation Format

Share Document